publication venue for
- Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. 30:100388-100388. 2021
- Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. 27:100351-100351. 2021
- Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review. 26:100345-100345. 2021
- Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. 26:100343-100343. 2021
- Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. 26:100339-100339. 2021
- Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. 10:6-13. 2018
- A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer. 5:173-179. 2016
- Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). 5:57-62. 2016
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. 4:47-53. 2015
- Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting. 3:1-4. 2014
- Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. 3:1-4. 2014
- A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. 2:123-131. 2013
- Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials. 2:70-76. 2013
- A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. 2:123-131. 2013